Results 241 to 250 of about 137,214 (262)

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023
Rujul Parikh
exaly  

The kinetics and temporal expression of T-cell activation-associated antigens CD15 (LeuM1), CD30 (Ki-1), EMA, and CD11c (LeuM5) by benign activated T cells.

Hematologic pathology, 1993
Cell surface antigens, including CD71 (T9), CD38 (T10), HLA-DR, CD25 (IL2-R), CD15 (LeuM1), CD30 (Ki-1), epithelial membrane antigen (EMA), and CD11c (LeuM5), have been identified on the surface of neoplastic T-cells. The significance of this expression is unknown since the expression of these antigens by benign T cells has not been fully investigated.
A, Chadburn, G, Inghirami, D M, Knowles
openaire   +1 more source

The diagnostic significance of the CD30 (Ki‐1) antigen

Histopathology, 1990
openaire   +2 more sources

A guide to antigen processing and presentation

Nature Reviews Immunology, 2022
Hidde Ploegh, Thibault Harmand, Novalia Pishesha   +2 more
exaly  

Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity

Cell, 2023
Leyuan Ma
exaly  

MR1 antigen presentation to MAIT cells and other MR1-restricted T cells

Nature Reviews Immunology, 2023
JOSÉ Villadangos, Hamish Eg Mcwilliam, Villadangos JOSÉ A   +2 more
exaly  

GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity

Cancer Cell, 2022
Kevin Parker, Anya Alag, Crystal Mackall   +2 more
exaly  

Prostate-specific antigen: current status

Ca-A Cancer Journal for Clinicians, 1999
M K Brawer
exaly  

Prostate-Specific Antigen and Premalignant Change: Implications for Early Detection

Ca-A Cancer Journal for Clinicians, 1989
M K Brawer, P H Lange
exaly  

How to use prostate-specific antigen in the early detection or screening for prostatic carcinoma

Ca-A Cancer Journal for Clinicians, 1995
M K Brawer
exaly